Drug Insights

Your Ultimate Guide to Finding Hydrocodone on Synapse

18 February 2024
2 min read

Hydrocodone bitartrate is a drug commonly used for pain relief, approved first in the United States. The drug works by binding to opioid receptors in the brain, acting as a mu/kappa/delta agonist. Its chemical name is 4,5(alpha)-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5) or morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, [R (R*, R*)]-2,3-dihydroxybutanedioate (1:1),hydrate (2:5). Hydrocodone bitartrate is widely used in the U.S. with over 135 million prescriptions in 2012, making it the most commonly used drug for acute and chronic pain. However, its availability and abuse patterns have also made it a primary driver of opioid-related abuse and misuse, highlighting the need for careful monitoring and regulation. Click on the image below to begin the exploration journey of Hydrocodone through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Incyte Secures Sole Worldwide Rights for Development and Sales of the Drug Tafasitamab (Monjuvi®)
Latest Hotspot
3 min read
Incyte Secures Sole Worldwide Rights for Development and Sales of the Drug Tafasitamab (Monjuvi®)
18 February 2024
Incyte has declared the establishment of an asset acquisition deal with MorphoSys AG, granting Incyte unique worldwide privileges for the drug tafasitamab.
Read →
An analysis of ADG-126's R&D progress and its clinical results presented at the 2024 ASCO_GI Annual Meeting
An analysis of ADG-126's R&D progress and its clinical results presented at the 2024 ASCO_GI Annual Meeting
18 February 2024
The latest clinical results of ADG-126 for metastatic MSS CRC treatment were shared at the 2024 ASCO_GI on Jan 20, 2024.
Read →
MorphoSys to merge with Novartis under a new deal, total purchase price set at €2.7 billion in stock value
Latest Hotspot
3 min read
MorphoSys to merge with Novartis under a new deal, total purchase price set at €2.7 billion in stock value
18 February 2024
MorphoSys AG has officially declared that it has formed a strategic alliance through a Business Merger Contract with Novartis data42 AG and the principal entity, Novartis AG.
Read →
Explore Valacyclovir on Synapse: Tips and Tricks for Better Search Results
Drug Insights
2 min read
Explore Valacyclovir on Synapse: Tips and Tricks for Better Search Results
18 February 2024
Valacyclovir Hydrochloride, sold under the brand name Valtrex, is an antiviral drug that was first approved in the USA in 1995.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.